KURA
Kura Oncology, Inc. (KURA) ESG Analysis Analysis (2026)
Overall Score
Environmental
No material environmental change this month; no new ESG-related news was provided.
R&D intensity remains high at 3.36x revenue, which can support innovation but also implies sustained resource use.
Social
No material social change this month; no new workforce, customer, or community news was provided.
Stock-based compensation remains elevated at 50.4% of revenue, which can affect employee alignment and dilution.
Governance
No material governance change this month; no new board, audit, or regulatory news was provided.
Liquidity remains strong with a current ratio of 4.73x and cash per share of 5.84, supporting financial resilience.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Kura Oncology, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

